SRPT
Sarepta Therapeutics, Inc.$21.11+0.13 (+0.62%)Prev Close$20.98·MCap$2.17B·P/E—·Vol1.50M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
8
$803.2K
◆
Net Activity
Net Seller
$803.2K
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Sarepta Therapeutics, Inc. (SRPT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 8 insider sales totaling $803.2K. The most recent insider transaction was by Mayo Stephen (director), who sold $123.2K worth of shares on Mar 13, 2026. Sarepta Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.17B.
SRPT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Mayo Stephen | director | Sell | 7,239 | $17.02 | $123.2K | 1,765-80% |
| Jan 29, 2026 | Nicaise Claude | Director | Sell | 6,780 | $21.23 | $143.9K | 0 |
| Jan 27, 2026 | BEHRENS M KATHLEEN | Director | Sell | 6,494 | $22.17 | $144.0K | 0 |
| Dec 16, 2025 | Estepan Ian Michael | Chief Operating Officer | Sell | 13,187 | $22.31 | $294.2K | 0 |
| Dec 1, 2025 | Wong Ryan Ho-Yan | Chief Financial Officer | Sell | 158 | $20.96 | $3.3K | 0 |
| Nov 28, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 229 | $21.12 | $4.8K | 0 |
| Nov 17, 2025 | Rodino-Klapac Louise | President, R&D and Tech Ops | Sell | 4,582 | $18.42 | $84.4K | 0 |
| Jul 31, 2025 | Wong Ryan Ho-Yan | Chief Financial Officer | Sell | 327 | $16.42 | $5.4K | 0 |
| Mar 12, 2025 | Nicaise Claude | Director | Sell | 2,491 | $99.64 | $248.2K | 0 |
| Mar 10, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 523 | $100.13 | $52.4K | 0 |
| Mar 10, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 491 | $100.13 | $49.2K | 0 |
| Mar 7, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 3,941 | $100.13 | $394.6K | 0 |
| Mar 7, 2025 | Murray Dallan | Chief Customer Officer | Sell | 3,733 | $100.13 | $373.8K | 0 |
| Mar 7, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 3,463 | $100.13 | $346.8K | 0 |
| Mar 7, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 1,478 | $103.70 | $153.3K | 0 |
| Mar 6, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 9,035 | $103.70 | $936.9K | 0 |
| Mar 6, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 9,679 | $103.70 | $1.00M | 0 |
| Mar 6, 2025 | Murray Dallan | Chief Customer Officer | Sell | 9,162 | $103.70 | $950.1K | 0 |
| Mar 6, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 8,504 | $103.70 | $881.9K | 0 |
| Mar 4, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 514 | $101.34 | $52.1K | 0 |
| Mar 4, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 1,370 | $101.34 | $138.8K | 0 |
| Mar 4, 2025 | Murray Dallan | Chief Customer Officer | Sell | 1,685 | $101.34 | $170.8K | 0 |
| Mar 4, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 1,704 | $101.34 | $172.7K | 0 |
| Mar 4, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 584 | $101.34 | $59.2K | 0 |
| Mar 3, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 719 | $103.77 | $74.6K | 0 |
| Mar 3, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 557 | $103.77 | $57.8K | 0 |
| Mar 3, 2025 | Murray Dallan | Chief Customer Officer | Sell | 711 | $103.77 | $73.8K | 0 |
| Mar 3, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 715 | $103.77 | $74.2K | 0 |
| Mar 3, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 391 | $103.77 | $40.6K | 0 |
| Dec 16, 2024 | Wigzell Hans Lennart Rudolf | Sell | 10,500 | $124.84 | $1.31M | 22,840-31% | |
| Dec 6, 2024 | Boor Kathryn Jean | Sell | 1,636 | $125.55 | $205.4K | 5,880 | |
| Sep 3, 2024 | Estepan Ian Michael | Chief Financial Officer | Sell | 5,985 | $137.36 | $822.1K | 33,946 |
| Aug 20, 2024 | Chambers Michael Andrew | Buy | 37,038 | $133.80 | $4.96M | 284,034 | |
| Jun 25, 2024 | Arif Bilal | Chief Tech Ops Officer | Sell | 11,757 | $163.13 | $1.92M | 23,540-33% |
| Jun 25, 2024 | Brown Ryan Edward | EVP, General Counsel | Sell | 38,957 | $161.61 | $6.30M | 48,442-45% |
| May 6, 2024 | Murray Dallan | Chief Customer Officer | Sell | 3,635 | $140.00 | $508.9K | 18,125 |
| Mar 11, 2024 | Boor Kathryn Jean | Sell | 761 | $122.93 | $93.5K | 7,516 | |
| Mar 11, 2024 | Wigzell Hans Lennart Rudolf | Sell | 15,000 | $123.25 | $1.85M | 34,685-30% | |
| Mar 6, 2024 | Mayo Stephen | Sell | 3,135 | $122.96 | $385.5K | 6,621-32% | |
| Mar 5, 2024 | Arif Bilal | Chief Tech Ops Officer | Sell | 2,000 | $128.84 | $257.7K | 27,293 |
| Mar 5, 2024 | Brown Ryan Edward | EVP, General Counsel | Sell | 2,000 | $125.34 | $250.7K | 31,827 |
| Mar 5, 2024 | Estepan Ian Michael | Chief Financial Officer | Sell | 1,200 | $128.30 | $154.0K | 39,114 |
| Nov 6, 2023 | Barry Richard | Director | Buy | 50,000 | $78.81 | $3.94M | 140,000+56% |
| Nov 6, 2023 | INGRAM DOUGLAS S | President & CEO | Buy | 25,225 | $79.36 | $2.00M | 390,307 |
| Aug 15, 2023 | Chambers Michael Andrew | Director | Buy | 9,979 | $109.47 | $1.09M | 246,996 |
| Aug 14, 2023 | Chambers Michael Andrew | Director | Buy | 23,686 | $108.05 | $2.56M | 237,017 |
| Aug 11, 2023 | Chambers Michael Andrew | Director | Buy | 34,867 | $106.15 | $3.70M | 213,331 |
| Aug 8, 2023 | Wigzell Hans Lennart Rudolf | Director | Sell | 15,000 | $106.72 | $1.60M | 20,994-42% |
| Nov 21, 2022 | Mayo Stephen | Director | Sell | 858 | $109.92 | $94.3K | 6,387 |
| Sep 15, 2022 | Chambers Michael Andrew | Director | Buy | 57,100 | $104.43 | $5.96M | 108,178+112% |
Showing 1–50 of 55
1 / 2
SRPT Insider Buying Activity
The following table shows recent insider purchases of Sarepta Therapeutics, Inc. (SRPT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 20, 2024 | Chambers Michael Andrew | Buy | 37,038 | $133.80 | $4.96M | 284,034 | |
| Nov 6, 2023 | Barry Richard | Director | Buy | 50,000 | $78.81 | $3.94M | 140,000+56% |
| Nov 6, 2023 | INGRAM DOUGLAS S | President & CEO | Buy | 25,225 | $79.36 | $2.00M | 390,307 |
| Aug 15, 2023 | Chambers Michael Andrew | Director | Buy | 9,979 | $109.47 | $1.09M | 246,996 |
| Aug 14, 2023 | Chambers Michael Andrew | Director | Buy | 23,686 | $108.05 | $2.56M | 237,017 |
| Aug 11, 2023 | Chambers Michael Andrew | Director | Buy | 34,867 | $106.15 | $3.70M | 213,331 |
| Sep 15, 2022 | Chambers Michael Andrew | Director | Buy | 57,100 | $104.43 | $5.96M | 108,178+112% |
SRPT Insider Selling Activity
The following table shows recent insider sales of Sarepta Therapeutics, Inc. (SRPT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Mayo Stephen | director | Sell | 7,239 | $17.02 | $123.2K | 1,765-80% |
| Jan 29, 2026 | Nicaise Claude | Director | Sell | 6,780 | $21.23 | $143.9K | 0 |
| Jan 27, 2026 | BEHRENS M KATHLEEN | Director | Sell | 6,494 | $22.17 | $144.0K | 0 |
| Dec 16, 2025 | Estepan Ian Michael | Chief Operating Officer | Sell | 13,187 | $22.31 | $294.2K | 0 |
| Dec 1, 2025 | Wong Ryan Ho-Yan | Chief Financial Officer | Sell | 158 | $20.96 | $3.3K | 0 |
| Nov 28, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 229 | $21.12 | $4.8K | 0 |
| Nov 17, 2025 | Rodino-Klapac Louise | President, R&D and Tech Ops | Sell | 4,582 | $18.42 | $84.4K | 0 |
| Jul 31, 2025 | Wong Ryan Ho-Yan | Chief Financial Officer | Sell | 327 | $16.42 | $5.4K | 0 |
| Mar 12, 2025 | Nicaise Claude | Director | Sell | 2,491 | $99.64 | $248.2K | 0 |
| Mar 10, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 523 | $100.13 | $52.4K | 0 |
| Mar 10, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 491 | $100.13 | $49.2K | 0 |
| Mar 7, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 3,941 | $100.13 | $394.6K | 0 |
| Mar 7, 2025 | Murray Dallan | Chief Customer Officer | Sell | 3,733 | $100.13 | $373.8K | 0 |
| Mar 7, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 3,463 | $100.13 | $346.8K | 0 |
| Mar 7, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 1,478 | $103.70 | $153.3K | 0 |
| Mar 6, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 9,035 | $103.70 | $936.9K | 0 |
| Mar 6, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 9,679 | $103.70 | $1.00M | 0 |
| Mar 6, 2025 | Murray Dallan | Chief Customer Officer | Sell | 9,162 | $103.70 | $950.1K | 0 |
| Mar 6, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 8,504 | $103.70 | $881.9K | 0 |
| Mar 4, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 514 | $101.34 | $52.1K | 0 |
| Mar 4, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 1,370 | $101.34 | $138.8K | 0 |
| Mar 4, 2025 | Murray Dallan | Chief Customer Officer | Sell | 1,685 | $101.34 | $170.8K | 0 |
| Mar 4, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 1,704 | $101.34 | $172.7K | 0 |
| Mar 4, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 584 | $101.34 | $59.2K | 0 |
| Mar 3, 2025 | Arif Bilal | Chief Tech Ops Officer | Sell | 719 | $103.77 | $74.6K | 0 |
| Mar 3, 2025 | Estepan Ian Michael | Chief Financial Officer | Sell | 557 | $103.77 | $57.8K | 0 |
| Mar 3, 2025 | Murray Dallan | Chief Customer Officer | Sell | 711 | $103.77 | $73.8K | 0 |
| Mar 3, 2025 | Rodino-Klapac Louise | Head of R&D, CSO | Sell | 715 | $103.77 | $74.2K | 0 |
| Mar 3, 2025 | Rothfuss Cristin | EVP, General Counsel | Sell | 391 | $103.77 | $40.6K | 0 |
| Dec 16, 2024 | Wigzell Hans Lennart Rudolf | Sell | 10,500 | $124.84 | $1.31M | 22,840-31% | |
| Dec 6, 2024 | Boor Kathryn Jean | Sell | 1,636 | $125.55 | $205.4K | 5,880 | |
| Sep 3, 2024 | Estepan Ian Michael | Chief Financial Officer | Sell | 5,985 | $137.36 | $822.1K | 33,946 |
| Jun 25, 2024 | Arif Bilal | Chief Tech Ops Officer | Sell | 11,757 | $163.13 | $1.92M | 23,540-33% |
| Jun 25, 2024 | Brown Ryan Edward | EVP, General Counsel | Sell | 38,957 | $161.61 | $6.30M | 48,442-45% |
| May 6, 2024 | Murray Dallan | Chief Customer Officer | Sell | 3,635 | $140.00 | $508.9K | 18,125 |
| Mar 11, 2024 | Boor Kathryn Jean | Sell | 761 | $122.93 | $93.5K | 7,516 | |
| Mar 11, 2024 | Wigzell Hans Lennart Rudolf | Sell | 15,000 | $123.25 | $1.85M | 34,685-30% | |
| Mar 6, 2024 | Mayo Stephen | Sell | 3,135 | $122.96 | $385.5K | 6,621-32% | |
| Mar 5, 2024 | Arif Bilal | Chief Tech Ops Officer | Sell | 2,000 | $128.84 | $257.7K | 27,293 |
| Mar 5, 2024 | Brown Ryan Edward | EVP, General Counsel | Sell | 2,000 | $125.34 | $250.7K | 31,827 |
| Mar 5, 2024 | Estepan Ian Michael | Chief Financial Officer | Sell | 1,200 | $128.30 | $154.0K | 39,114 |
| Aug 8, 2023 | Wigzell Hans Lennart Rudolf | Director | Sell | 15,000 | $106.72 | $1.60M | 20,994-42% |
| Nov 21, 2022 | Mayo Stephen | Director | Sell | 858 | $109.92 | $94.3K | 6,387 |
SRPT Insiders
Similar Stocks to SRPT
VRTX
Vertex Pharmaceuticals Incorporated
$429.80+0.86%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.48-1.65%
$41.24B
INSM
Insmed Incorporated
$135.19-0.65%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.57+9.80%
$29.51B
UTHR
United Therapeutics Corporation
$566.96+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.17-3.20%
$21.42B
RPRX
Royalty Pharma plc
$49.41-0.47%
$21.20B